Windlas Biotech Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 33.7% CAGR over last 5 years
- Company is almost debt free
- Company has consistently been profitable over the last 5 years
- Company has delivered good sales growth of 16.2% CAGR over last 5 years
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.52x)
CONS
- Receivables are growing faster than sales - a possible quality concern
- Valuation is stretched - P/E of 35.7 is well above its own 5-year median (23.4)
- Growth is decelerating - 3Y profit CAGR (16.0%) trails the 5Y trend (33.7%)
- Expensive relative to growth - PEG of 2.2
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1881.10 | 37.31 | 451338.90 | 0.85 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9570.55 | 86.86 | 254068.03 | 0.31 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4962.75 | 86.55 | 188767.06 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1150.00 | 25.42 | 114712.94 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1383.95 | 33.17 | 111803.57 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1945.50 | 96.14 | 105117.74 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1686.00 | 26.13 | 97008.71 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2112.00 | 17.47 | 96574.55 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1151.50 | 29.83 | 96113.39 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2305.85 | 46.63 | 95242.00 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2477.35 | 38.89 | 69916.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| WINDLAS | 1148.40 | 35.66 | 2369.86 | 0.55 | 15.99 | -1.79 | 238.50 | 17.66 | 16.06 | 10.60 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 141 | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 | |
| 124 | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 | |
| Operating Profit | 16 | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 |
| OPM % | 11.68% | 11.84% | 12.24% | 12.53% | 12.85% | 11.92% | 12.33% | 12.63% | 12.60% | 12.62% | 12.84% | 10.45% | 10.60% |
| 2 | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 |
| Profit before Tax | 15 | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 |
| Tax % | 23.94% | 26.19% | 23.38% | 23.78% | 24.92% | 26.38% | 22.82% | 23.40% | 21.81% | 24.03% | 24.54% | 24.89% | 20.68% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 13 | 16 | 16 | 16 | 18 | 18 | 15 | 16 |
| 5.37 | 5.79 | 6.75 | 7.26 | 8.17 | 6.47 | 7.49 | 7.45 | 7.77 | 8.43 | 8.48 | 7.12 | 7.58 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 352 | 307 | 329 | 428 | 466 | 513 | 631 | 760 | 904 | 904 | |
| 313 | 269 | 287 | 373 | 414 | 453 | 553 | 666 | 799 | 799 | |
| Operating Profit | 39 | 39 | 41 | 55 | 52 | 60 | 78 | 94 | 105 | 105 |
| OPM % | 11.17% | 12.53% | 12.61% | 12.79% | 11.25% | 11.74% | 12.39% | 12.38% | 11.59% | 11.59% |
| 4 | 54 | 2 | -19 | 7 | 10 | 13 | 18 | 18 | 18 | |
| Interest | 6 | 5 | 3 | 1 | 1 | 1 | 1 | 4 | 5 | 5 |
| Depreciation | 17 | 11 | 9 | 13 | 12 | 12 | 13 | 28 | 31 | 31 |
| Profit before Tax | 20 | 76 | 25 | 22 | 46 | 57 | 77 | 80 | 87 | 87 |
| Tax % | 43.59% | 16.15% | 34.28% | 28.38% | 16.41% | 25.27% | 24.52% | 23.53% | 23.59% | 23.59% |
| Net Profit | 11 | 64 | 16 | 16 | 38 | 43 | 58 | 61 | 66 | 66 |
| EPS | 6.80 | 37.65 | 8.90 | 8.70 | 18.58 | 19.70 | 27.98 | 29.10 | 31.49 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 20.03% | 19.64% | 19.66% | 19.93% | 20.01% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 16%
- 3 Years:
- 21%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 33%
- 3 Years:
- 16%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- 24%
- 3 Years:
- 45%
- 1 Year:
- 14%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 13%
- 3 Years:
- 13%
- Last Year:
- 13%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 | |
| 117 | 187 | 203 | 193 | 382 | 389 | 435 | 490 | 551 | |
| 57 | 31 | 29 | 32 | 6 | 4 | 2 | 29 | 32 | |
| Trade Payables | 85 | 58 | 83 | 40 | 63 | 88 | 132 | 178 | 238 |
| 25 | 15 | 16 | 25 | 26 | 36 | 47 | 52 | 75 | |
| Total Liabilities | 289 | 298 | 338 | 296 | 489 | 527 | 626 | 760 | 907 |
| 86 | 64 | 70 | 96 | 91 | 109 | 179 | 223 | 213 | |
| Capital Work in Progress | 11 | 5 | 0 | 0 | 8 | 14 | 6 | 3 | 56 |
| 23 | 122 | 116 | 23 | 65 | 107 | 173 | 223 | 268 | |
| 35 | 19 | 49 | 41 | 59 | 75 | 62 | 81 | 62 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 136 | 167 | 227 | |
| Cash & Bank | 8 | 13 | 18 | 31 | 114 | 25 | 31 | 16 | 2 |
| 127 | 74 | 84 | 104 | 153 | 197 | 38 | 46 | 78 | |
| Total Assets | 289 | 298 | 338 | 296 | 489 | 527 | 626 | 760 | 907 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 40 | 31 | 38 | 18 | 18 | 71 | 109 | 68 | 105 | |
| Cash from Investing | -11 | -5 | -14 | -20 | -155 | -14 | -92 | -74 | -92 |
| Cash from Financing | -26 | -6 | -5 | 1 | 130 | -44 | -15 | 1 | -13 |
| -2 | 7 | 5 | -8 | -15 | 3 | 2 | -5 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-01 - Windlas Biotech Limited has informed the Exchange about Schedule of meet
2026-08-14 - Windlas Biotech Limited has informed the Exchange about earnings call transcript of Q1 FY27
2026-08-11 - Windlas Biotech Limited has informed the Exchange about Link of Recording
2026-08-10 - Windlas Biotech Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "press release on "Windlas Biotech Limited Reports its Q1 FY27 Financial Results"".
2026-08-10 - Windlas Biotech Limited has informed the Exchange about Investor Presentation
2026-08-10 - Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-05 - Windlas Biotech Limited has informed the Exchange about Schedule of meet
2026-08-05 - Windlas Biotech Limited has informed the Exchange about Schedule of meet
2026-07-24 - Submission of Combined Voting Results and Scrutinizer s Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ) of the 25th Annual General Meeting held on July 23, 2026
News
Recent coverage and analyst commentary for WINDLAS
Loading news…
AI Stock Analyst
Windlas Biotech Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account